{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:25:41Z","timestamp":1787631941999,"version":"build-2736575974"},"reference-count":114,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["aao-hnsfjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngol.--head neck surg."],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Intratympanic injections are a safe, well tolerated procedure routinely performed by ENT's specialists. Intratympanic injections of gels have the potential to deliver therapeutics into the cochlea through the round window membrane prolonging the release of drugs in the inner ear compartment. Aim of the present review is to summarize clinical trials testing pharmacological treatments for inner ear pathologies through intratympanic gel formulations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data Sources<\/jats:title><jats:p>Online databases (Google scholar and PubMed) and registers (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/Clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link> and Euclinicaltrial) were used to identify clinical trials performed between 1990 and 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Review Methods<\/jats:title><jats:p>PRISMA criteria have been followed. Clinical trials testing gel formulations administered through local intratympanic injections and targeting inner ear disorders were included. All the reports were identified by the authors working in pairs sequentially selecting only studies respecting the inclusion criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 45 clinical studies have been noticed; the gels for intratympanic injection are in the form of poloxamers or hyaluronic acid combinations; the trials found target different kind of inner ear disorders: acquired\u2010stable SNHL, tinnitus, acute sudden SNHL, Meniere disease, cisplatin induced ototoxicity and hearing preservation in patients undergoing cochlear implant surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Few studies listed do not provide the specific kind of gel formulation used but only report the intratympanic delivery vehicle as \u201cgel\u201d or \u201cthermogel\u201d. Multiple clinical studies have been targeting several forms of inner ear disorders by injecting different compounds through poloxamer and hyaluronic acid formulations. Larger and more advanced clinical stages are necessary to confirm the efficacy of these chemical compounds.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ohn.656","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T05:58:46Z","timestamp":1706939926000},"page":"1613-1629","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intratympanic Gels for Inner Ear Disorders: A Scoping Review of Clinical Trials"],"prefix":"10.1002","volume":"170","author":[{"given":"Davide","family":"Brotto","sequence":"first","affiliation":[{"name":"Department of Neuroscience DNS, Otolaryngology Section Padova University Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Greggio","sequence":"additional","affiliation":[{"name":"Department of Neuroscience DNS, Degree Course in Audiometric Techniques Padova University Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"WHO Deafness and hearing loss;2021.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/deafness-and-hearing-loss"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2013.01.021"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.24439"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.11310.1"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62071-7"},{"key":"e_1_2_7_7_1","article-title":"Meni\u00e8re's disease","volume":"2015","author":"Wright T","year":"2015","journal-title":"BMJ Clin Evid"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-6123-4_5"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.603"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mph.0000141348.62532.73"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.5355"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22004"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e318059c220"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2016.1700"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2217\/rme.13.32"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.739608"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.11.009"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000241892"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720112800389098"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2018.05.020"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00238"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2013.02.003"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.08.015"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.01.004"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.26394"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000003709"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000241896"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000322504"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2004.09.028"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/03639040500390934"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2023.38.e135"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/000348941212100311"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000000445"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.02.013"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/03639045.2017.1373803"},{"key":"e_1_2_7_36_1","first-page":"35","article-title":"Sodium hyaluronate application to the open inner ear: an ultrastructural investigation","volume":"12","author":"Bagger\u2010Sj\u00f6b\u00e4ck D","year":"1991","journal-title":"Am J Otol"},{"key":"e_1_2_7_37_1","first-page":"501","article-title":"Hyaluronic acid in middle ear surgery","volume":"14","author":"Bagger\u2010Sj\u00f6b\u00e4ck D","year":"1993","journal-title":"Am J Otol"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.127.5.534"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2008.07.012"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/0003489419830116"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/0003489415599001"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2016.0001"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0194599816645526"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2017.12.016"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mao.0000185050.69394.48"},{"key":"e_1_2_7_46_1","unstructured":"2016\u2010004544\u201010 A phase I\/II multiple ascending dose open\u2010label safety and efficacy study of the Notch Inhibitor LY3056480 in patients with mild to moderate sensorineural hearing loss.https:\/\/www.clinicaltrialsregister.eu\/"},{"key":"e_1_2_7_47_1","unstructured":"NCT05061758 A trial of LY3056480 in Patients With SNHL (VESTA). Accessed August 25 2022.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000003120"},{"key":"e_1_2_7_49_1","unstructured":"NCT03300687 First in Humans Safety Study of FX\u2010322 in Adults undergoing cochlear Implantation. Accessed April 12 2018.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_50_1","unstructured":"NCT05086276 FX\u2010322 in Adults With Acquired sensorineural hearing loss. Accessed January 31 2023.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_51_1","unstructured":"NCT04120116 FX\u2010322 in Adults With Stable Sensorineural Hearing Loss. Accessed October 31 2022.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_52_1","unstructured":"NCT04601909 FX\u2010322 in Adults With Age\u2010Related Sensorineural Hearing Loss. Accessed May 25 2022.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_53_1","unstructured":"NCT04629664 FX\u2010322 in Adults With Severe Sensorineural Hearing Loss. Accessed February 1 2022.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_54_1","unstructured":"NCT05664100 First in human safety study of FX\u2010345 in adults with sensorineural hearing loss. Accessed December 23 2022.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_55_1","unstructured":"NCT04129775 OTO\u2010413 in Subjects With Speech\u2010in\u2010Noise Hearing Impairment. Accessed October 27 2022.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.710159"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.01.066"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224022"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1121\/10.0011510"},{"key":"e_1_2_7_60_1","unstructured":"Otonomy Inc.https:\/\/investors.otonomy.com\/news-releases\/news-release-details\/otonomy-reports-results-clinical-evaluation-oto-413-higher-doses"},{"key":"e_1_2_7_61_1","unstructured":"FrequencyTherapeutics Inc.https:\/\/investors.frequencytx.com\/news-releases\/news-release-details\/frequency-therapeutics-announces-topline-results-its-phase-2b"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1159\/000046864"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-09-03944.2003"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1155\/2007\/80904"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1159\/000322641"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000000268"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1159\/000369608"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1177\/0194599817711378"},{"key":"e_1_2_7_69_1","unstructured":"NCT01934010 AM\u2010101 in the Treatment of Post\u2010Acute Tinnitus 1 (AMPACT1). Accessed May 16 2018.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_70_1","unstructured":"NCT02040207 AM\u2010101 in the Treatment of Post\u2010Acute Tinnitus 2 (AMPACT2). Accessed January 19 2017https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_71_1","unstructured":"NCT02040194 AM\u2010101 in the Treatment of Acute Tinnitus 3 (TACTT3). Accessed January 16 2018.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000003369"},{"key":"e_1_2_7_73_1","unstructured":"NCT04829214 OTO\u2010313 in Subjects With Unilateral Subjective Tinnitus. Accessed January 6 2023.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_74_1","unstructured":"Otonomy Inc.https:\/\/investors.otonomy.com\/news-releases\/news-release-details\/otonomy-reports-results-phase-2-clinical-trial-oto-313-patients"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mao.0000185052.07513.5a"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-24-08596.2003"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.106.028936"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLG.0b013e3181461f92"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2006.05.006"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.20759"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0b013e3182355658"},{"issue":"1","key":"e_1_2_7_82_1","first-page":"S1","article-title":"Molecular mechanisms involved in cochlear implantation trauma and the protection of hearing and auditory sensory cells by inhibition of c\u2010Jun\u2010N\u2010terminal kinase signaling","volume":"123","author":"Eshraghi AA","year":"2013","journal-title":"Laryngoscope"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2018.03.003"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1080\/00016480601110212"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000000466"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000002229"},{"key":"e_1_2_7_87_1","unstructured":"NCT02809118 Efficacy and Safety of AM\u2010111 as Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). Accessed August 7 2020.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-004-0772-6"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0b013e31821a3fc3"},{"issue":"94","key":"e_1_2_7_90_1","first-page":"255","article-title":"Therapeutic effect of intra\u2010tympanic dexamethasone\u2010hyaluronic acid combination in sudden sensorineural hearing loss","volume":"29","author":"Rogha M","year":"2017","journal-title":"Iran J Otorhinolaryngol"},{"key":"e_1_2_7_91_1","unstructured":"2017\u2010000242\u201022 A Phase III multicenter double\u2010blind placebo\u2010controlled study evaluating the safety and efficacy of STR001 treatment (intratympanic injection + tablets) in adults with Sudden Sensorineural Hearing Loss.https:\/\/www.clinicaltrialsregister.eu\/"},{"key":"e_1_2_7_92_1","unstructured":"2021\u2010004323\u201033 Phase II Multi\u2010Center Randomized Blinded Study Evaluating the Efficacy Safety and Tolerability of a Single Intratympanic Dose of AC102 Compared to Oral Steroids for the Treatment of Idiopathic sudden sensorineural hearing loss.https:\/\/www.clinicaltrialsregister.eu\/"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0b013e318263d35d"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000001227"},{"key":"e_1_2_7_95_1","unstructured":"NCT02740387 Open Label Study of OTO\u2010104 in Subjects With Meniere's Disease. Accessed September 15 2017.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_96_1","unstructured":"NCT02265393 A 1\u2010Year Safety Study of OTO\u2010104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom. Accessed August 18 2017.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_97_1","unstructured":"NCT02768662 A 6\u2010Month Extension Study of OTO\u2010104 in Meniere's Disease. Accessed January 20 2023.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_98_1","unstructured":"NCT02706730 A 6\u2010Month Extension Study of OTO\u2010104 in Meniere's Disease. Accessed December 14 2022.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_99_1","unstructured":"NCT02717442 Study of OTO\u2010104 in Subjects With Unilateral Meniere's Disease (AVERTS\u20102). Accessed January 13 2023.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_100_1","unstructured":"NCT02612337 Study of OTO\u2010104 in Subjects With Unilateral Meniere's Disease (AVERTS\u20101). Accessed January 12 2023.https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_101_1","unstructured":"NCT03664674 Phase 3 Study of OTO\u2010104 in Subjects With Unilateral Meniere's Disease. Last update on December 7 2022https:\/\/clinicaltrials.gov\/"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0b013e3182009d29"},{"key":"e_1_2_7_103_1","unstructured":"Otonomy Inc.https:\/\/investors.otonomy.com\/news-releases\/news-release-details\/otonomy-initiates-phase-3-clinical-trial-otividextm-menieres"},{"key":"e_1_2_7_104_1","unstructured":"Otonomy Inc.https:\/\/investors.otonomy.com\/news-releases\/news-release-details\/otonomy-announces-top-line-results-phase-3-clinical-trial"},{"issue":"2","key":"e_1_2_7_105_1","first-page":"196","article-title":"Dexamethasone inner ear perfusion for the treatment of Meniere's disease: a prospective, randomized, double\u2010blind, crossover trial","volume":"19","author":"Silverstein H","year":"1998","journal-title":"Am J Otol"},{"issue":"105","key":"e_1_2_7_106_1","first-page":"217","article-title":"Therapeutic effect of intratympanic injection of dexamethasone plus hyaluronic acid on patients with Meniere's disease","volume":"31","author":"Rogha M","year":"2019","journal-title":"Iran J Otorhinolaryngol"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40463-019-0327-x"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00918-1"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000003069"},{"key":"e_1_2_7_110_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801109"},{"key":"e_1_2_7_111_1","unstructured":"DecibelTherapeutics Inc.https:\/\/ir.decibeltx.com\/news-releases\/news-release-details\/decibel-therapeutics-reports-positive-data-interim-analysis"},{"key":"e_1_2_7_112_1","unstructured":"NCT02997189 Study of OTO\u2010104 in Subjects at Risk From Cisplatin\u2010Induced Hearing Loss. Accessed September 16 2020."},{"key":"e_1_2_7_113_1","unstructured":"2015\u2010002672\u201025 A Phase II multicenter placebo\u2010controlled proof\u2010of\u2010concept study evaluating the safety and efficacy of intratympanic STR001 thermogel to preserve residual hearing in adults undergoing cochlear implant surgery.https:\/\/www.clinicaltrialsregister.eu\/"},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.21370"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1159\/000313506"}],"container-title":["Otolaryngology\u2013Head and Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ohn.656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:03:50Z","timestamp":1760958230000},"score":1,"resource":{"primary":{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/10.1002\/ohn.656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,3]]},"references-count":114,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1002\/ohn.656"],"URL":"https:\/\/doi.org\/10.1002\/ohn.656","archive":["Portico"],"relation":{},"ISSN":["0194-5998","1097-6817"],"issn-type":[{"value":"0194-5998","type":"print"},{"value":"1097-6817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,3]]},"assertion":[{"value":"2023-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}